Mar 12, 2011

AstraZeneca to Pay $68.5 Million to U.S. States Over Seroquel Marketing

Alzheimer's Reading Room

AstraZeneca Plc (AZN) agreed to pay $68.5 million to 37 U.S. states and the District of Columbia to resolve allegations that the company deceptively marketed its anti-psychotic drug Seroquel.

The settlement, announced today, is separate from a $520 million agreement London-based AstraZeneca reached with the U.S. last year over the marketing of Seroquel, said Tony Jewell, a company spokesman.


The company marketed Seroquel for uses that weren’t approved by the U.S. Food and Drug Administration, the federal and state governments claimed.

AstraZeneca promoted the drug, approved for schizophrenia and bipolar disorder, for dementia, depression and anxiety in violation of federal drug rules, according to the states.

While doctors can prescribe medicines for other diseases, companies aren’t allowed to market drugs beyond approved uses.

Read more at Bloomberg.



Subscribe to the Alzheimer's Reading Room Enter your email address:

Read More on the Alzheimer's Reading Room

The Alzheimer's Action Plan

 

The 36-Hour Day



Bob DeMarco is the Founder of the Alzheimer's Reading Room and an Alzheimer's caregiver. The blog contains more than 2,255 articles with more than 272,100 links on the Internet. Bob resides in Delray Beach, FL.

Original content Bob DeMarco, the Alzheimer's Reading Room